Articles On Neurotech International (ASX:NTI)

Mike Tyson has spoken out against the jailing of cannabis users Iron Mike owns his own cannabis brand called TYSON 2.0 We take a look at the best performing ASX weed stocks over the past month    There are currently at least 3,000 individ...

  ASX200 drops about 0.7pc on Wednesday Consumer Staples craters, as WOW CEO departs Small Caps led by diggers IXR, AW1 and the biopharma Alterity   The ASX200 has ended lower on Wednesday, tracking losses in New York as traders brace – a...

Neurotech International (ASX: NTI) has announced “highly significant” improvements during the extension phase of a clinical trial into the impact of its lead candidate NTI164 on children with paediatric autoimmune neuropsychiatric disorders...

Biotech doesn’t need another pandemic for a resurgence – it’s made a strong comeback regardless. Stockhead spoke with Andrew Chapman, head of Perth-based fundie Merchant Group – to learn why this is the case, and which are his top picks for...

Neurotech International (ASX: NTI) is currently running a Phase I/II clinical trial for Rett Syndrome.

Immuron reports record sales for Travelan in January Neurotech extends Phase 1/2 clinical trial for benefit of patients   Immuron’s record sales Immuron (ASX:IMC) has just announced record sales (unaudited) for Travelan for the January pe...

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has received a 52-week extension to its trial of a potential medicinal cannabis plant extract treatment for children with autism spectrum disorder (ASD)...

  ASX to rise as Dow Jones hits fresh record Chipmaker Arm rises by almost 30pc Bitcoin has topped US$50k   The ASX is poised to rise on Monday after a mixed session in New York. At 8am AEDT, the ASX 200 index futures contract was pointi...

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has updated the market on the progress of its world-first Phase I/II clinical trial examining the daily use of proprietary broad-spectrum cannabinoid dr...

Neurotech says due to often negative publicity around cannabis companies it tends not to promote itself as one Neurotech taking drug development approach to lead product NTI164, meaning it will be registered as a prescription-only BOD Aust...

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has been recognised for its breakthrough development in the proposed treatment of paediatric neurological disorders with the grant of a $3.17 million re...

  Neurotech has a clear path for development and commercialisation of NTI164 to treat PANDAS/PANS With no approved therapy for PANDAS/PANS Neurotech is pursing orphan drug designation for NTI164 Results of Neurotech’s phase 1/2 trial inves...

Neurotech International (ASX: NTI) continues to make excellent progress in accelerating its specialist medical solutions for the treatment of neurological disorders. The company is refining the use of its NTI164 treatment to help overcome a...

Paediatric patients with PANDAS/PANS treated with Neurotech’s NTI164 showed marked improvements Anxiety and depression levels in patients reduced by 30% whilst severity of illness sees 18% improvement Results from genomic analysis of patie...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Paediatric neurological disorders specialist Neurotech International (ASX: NTI) has received promising results from its trial of potential treatments for the Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Inf...

Benchmark index falls to 11-month lows Utilities only sector in green Small caps led by Noxopharm   Local markets have extended unexpected October losses on Wednesday as tech stocks, and the Financial Sector led losses on another bond-...

Clinical-stage biopharmaceutical company Neurotech International (ASX: NTI) has completed the recruitment of 14 patients into a Phase I/II clinical trial investigating the use of lead candidate NTI164 in females with Rett Syndrome. The 16-w...

Cannabis stocks are rebounding, catching short sellers off guard Next signpost for weed investors is the Section 280E of the US IRS tax code We take a look at the best performing weed stocks in last couple of weeks   Having been mauled fo...

2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead the pack  Neuren’s results of Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome due in December Antisense Therapeutics Phase2b t...

Stockhead’s Top 10 at shortly-before-11-ish, published once our panel of the world’s best chocolatiers have sampled the wares, and deemed them worthy to be displayed in the fanciest windows of the fanciest stores, in the fanciest cities of...

Several ASX companies are undergoing rigorous clinical trials to gain regulatory approval for their cannabinoid products BOD Australia could have the first Schedule 3 CBD product in Australia following positive results from its Phase 2B Ca...

A unique Australian trial currently being conducted by Neurotech International (ASX: NTI) is looking to make a breakthrough in the treatment of major paediatric neurological disorders. Speaking at a special seminar today, professor Russell...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Cannabis stocks jumped after marijuana rescheduling recommendation in the US Study in Australia shows cannabis is effective on a range of conditions We take a look at the best performing ASX stocks over the past week   Cannabis stocks ope...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Biopharmaceutical development company Neurotech International (ASX: NTI) has achieved a last patient-last visit (LPLV) milestone for its Phase I/II clinical trial of lead drug NTI164 in children diagnosed with paediatric autoimmune neuropsy...

Futures point to the ASX opening fairly flat this morning on another busy day of reporting. Today, the Bank of Queensland, IGO, Sandfire Resources and Harvey Norman will all release their results. Here are some stocks to watch for you...

MoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and analysts are looking at right now. Today we hear from Andrew Chapman, managing director of Merchant Group Australia.   What sector is hot r...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has reached a critical milestone with the dosing of the initial patient using its unique treatment for Rett Syndrome. The first patient has now been enr...

The ASX 200 had a positive finish to the day on the whole, on the back of the rates pause from the RBA Sectors were a green scene, with IT and Staples leading the way Standout small caps: Viridis, Imricor and Baby Bunting, among several ot...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has updated the market on progress of its lead candidate cannabinoid-based drug...

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has updated the market on progress of its lead candidate cannabinoid-based drug NTI164 to treat several paediatric neurological disorders where there is...

Neurotech is following in the footsteps of 2023 market darling of the ASX biotech sector Neuren with another possible treatment for Rett Syndrome. Biopharmaceutical company Neurotech International (ASX:NTI) has hopes of becoming the world’...

Social media platforms are rushing to update their advertising policies on cannabis Meta was the most recent platform to do so Australia’s TGA is clamping down on CBD advertising in Australia   With regulations on cannabis use moving fast...

With the Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) scheme clearance by the Therapeutic Goods Administration (TGA) under its wing, Neurotech will investigate the use of NTI164 in female Rett Syndro...

This content is created by Smallcaps Authors. [Author : Colin Hay] Specialist biopharmaceutical development company Neurotech International (ASX: NTI) has obtained critical approval to undergo testing of a potential treatment for Rett Syn...

Bod Science provided a ‘landmark update’ on its Phase IIB insomnia clinical trial Neurotech received an ethics approval to begin Phase I/II clinical trial Incannex intends to list all its shares on the Nasdaq   Bod Science provides ‘landm...

Zelira announced that its diabetic nerve pain drug outperforms Pfizer’s Lyrica Diabetes is a huge market, estimated at a massive US$62 billion in 2022 Stockhead reached out to Zelira’s CEO, Dr. Oludare Odumosu   Diabetes is one of the lea...

The weed industry has slumped as it faces several headwinds But new data suggests the industry will grow significantly over the next decade We take a look at how the ASX weed stocks have performed over the past week   As we head into the...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] The Human Research Ethics Committee (HREC) has granted Neurotech International (ASX: NTI) a two-year dosage extension for the use of lead drug NTI164 on autism spectru...

Neurotech will extend its Phase 1/2 trial after ethics approval Alcidion makes further inroads into UK’s public hospitals   Neurotech to extend Phase 1/2 trial after ethics approval Paediatric neurological disorders specialist, Neurotech...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has received Human Research Ethics Committee (HREC) approval to extend a curren...

Studies confirm that cannabis relieves pain in cancer patients In addition, cannabis also improves sleep and cognitive function in cancer patients We take a look at the biggest movers in ASX weed stocks over the past week   It’s now offic...

This content is created by Smallcaps Authors. [Author : Lorna Nicholas] Neurotech International (ASX: NTI) has completed recruitment for a phase I/II trial assessing its lead candidate NTI164 in children with paediatric autoimmune neurops...

This content is created by Smallcaps Authors. [Author : Lorna Nicholas] Clinical stage biopharmaceutical company Neurotech International’s (ASX: NTI) plans for its phase II trial evaluating its NTI164 candidate in children with Rett syndr...

Chemist Warehouse joins WNX JV to develop new cannabis products Neurotech launches new clinical program for its NTI164 drug in Rett Syndrome InhaleRx nabs approval for Phase 1 IRX211 clinical trial for Complex Regional Pain Syndrome   Wel...